ArticleDiscover oncology2025
The global, regional, and national burden of acute lymphoblastic leukemia, 1990 to 2021: a cross-sectional analysis from the 2021 global burden of disease study.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Long Non-Coding RNA Expression in B-Cell Precursor Acute Lymphoblastic Leukemia: Analysis of LINC-PINT, MEG3, BALR6, and ZEB1-AS1.Life (Basel, Switzerland) · 2026Article
- Long-term trends in the burden of leukemia subtypes in China from 1990 to 2021: a Joinpoint regression and age-period-cohort analysis based on GBD 2021.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundAcute lymphoblastic leukemia (ALL) remains a major public health challenge, yet its global burden and epidemiological trends are inadequately characterized. This study evaluates the global burden of ALL from 1990 to 2021 and projects trends through 2040.
methodsUsing data from the Global Burden of Disease (GBD) Study 2021, we analyzed prevalence, incidence, mortality, disability-adjusted life years (DALYs), and age-standardized rates (ASRs) for ALL, stratified by time, region, age, and Socio-Demographic Index (SDI). Advanced methods included estimated annual percentage change (EAPC), Joinpoint regression, decomposition and frontier analyses, and Bayesian Age-Period-Cohort (BAPC) modeling to quantify trends, inequalities, and projections.
resultsIn 2021, ALL caused 386,813 prevalent cases globally (10.3% increase since 1990) and 71,221 deaths (41.8% decline). Age-standardized prevalence rate (ASPR) rose from 4.1 to 5.4 per 100,000 (EAPC = 1.4), while mortality rate (ASMR) decreased significantly (EAPC = - 1.73). High SDI regions exhibited the highest ASPR (16.1 vs. 1.3 per 100,000 in low-SDI areas) but lower ASMR (0.5 vs. 1.3) and DALY rates (23.7 vs. 47.9). A bimodal age distribution peaked in children < 5 years (21.5 per 100,000), with male predominance across ages. Modifiable risks included high BMI (5.8% of global deaths) and smoking (15.4% in high-income North America). Health inequalities widened: the slope index of inequality for prevalence increased from 3.22 to 4.23 (1990-2021), and ASDR disparity reached - 30.97. Frontier analysis highlighted untapped ASDR reduction potential in low-SDI nations (97.17-136.34 per 100,000). Projections suggest a 50% global ASPR decline by 2040 (2.84 per 100,000), though regional disparities persist.
conclusionThe global ALL burden reflects progress and disparity: high-SDI regions face rising prevalence and aging-related challenges despite mortality declines, while low-SDI areas grapple with entrenched inequities. Age- and sx-specific patterns, alongside modifiable risks, necessitate targeted prevention and equity-driven policies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.